Lynkuet is the first and only dual neurokinin 1 and 3 (NK1/NK3) receptor antagonist approved for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. By blocking NK1 and NK3 receptor signaling in the hypothalamic thermoregulatory center, Lynkuet helps reduce the frequency and severity of hot flashes, both during the day and at night. Supported by the Phase III OASIS clinical program, this once-daily, nonhormonal oral therapy offers women an effective and convenient new option for managing menopausal symptoms.